Network-based microbial compositions and methods
US-10076546-B2 · Sep 18, 2018 · US
Synergistic bacterial compositions and methods of production and use thereof
US11464812B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11464812-B2 |
| Application number | US-202017120671-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 14, 2020 |
| Priority date | Nov 23, 2012 |
| Publication date | Oct 11, 2022 |
| Grant date | Oct 11, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Provided are therapeutic compositions containing Ecobiotic™ populations for prevention, treatment and reduction of symptoms associated with a dysbiosis of a mammalian subject such as a human.
First claim
Opening claim text (preview).
What is claimed is: 1. A composition comprising a first species of isolated bacterium and a second species of isolated bacterium and a capsule, which encapsulates the first species, the second species, or both the first and second species of isolated bacterium, wherein the first species is Lachnospiraceae_bacterium_ 5_1_57FAA and the second species is Clostridium disporicum , wherein the Lachnospiraceae_bacterium_ 5_1_57FAA FAA comprises a 16S rDNA sequence that is at least 97% identical to the 16S rDNA sequence set forth in SEQ ID NO: 979, and wherein the first species and the second species are capable of inhibiting Clostridium difficile ( C. difficile ) growth as measured by a CivSim assay. 2. The composition of claim 1 , which further comprises an enteric coating. 3. The composition of claim 1 , wherein the first species and the second species are capable of inhibiting C. difficile growth in the CivSim assay with a confidence interval of >99% (++++). 4. The composition of claim 1 , wherein the first species, the second species, or both are in the form of spores. 5. The composition of claim 1 , which is formulated for populating the gastrointestinal tract of the subject. 6. The composition of claim 1 , wherein the first species, the second species, or both are lyophilized. 7. A kit comprising in one or more containers the composition of claim 1 . 8. A pharmaceutical formulation comprising the composition of claim 1 . 9. The pharmaceutical formulation of claim 8 , further comprising an additional agent. 10. The pharmaceutical formulation of claim 9 , wherein the additional agent is selected from an anti-bacterial agent, anti-fungal agent, anti-viral agent, anti-parasitic agent, or combinations thereof. 11. The composition of claim 1 , wherein the Lachnospiraceae_bacterium_ 5_1_57FAA comprises a 16S rDNA sequence that is at least 98% identical to SEQ ID NO: 979. 12. The composition of claim 1 , wherein the Lachnospiraceae_bacterium_ 5_1_57FAA comprises a 16S rDNA sequence that is at least 99% identical to SEQ ID NO: 979. 13. The composition of claim 1 , wherein the Clostridium disporicum comprises a 16S rDNA sequence that is at least 97% identical to SEQ ID NO: 518. 14. The composition of claim 1 , wherein the Clostridium disporicum comprises a 16S rDNA sequence that is at least 98% identical to SEQ ID NO: 518. 15. The composition of claim 1 , wherein the Clostridium disporicum comprises a 16S rDNA sequence that is at least 99% identical to SEQ ID NO: 518. 16. The pharmaceutical formulation of claim 8 , which further comprises a pharmaceutically acceptable excipient. 17. The pharmaceutical formulation of claim 8 , which is formulated for oral administration. 18. The composition of claim 1 , which further comprises glycerol. 19. The composition of claim 1 , wherein the Lachnospiraceae_bacterium_ 5_1_57FAA comprises the 16S rDNA sequence set forth in SEQ ID NO: 979. 20. The composition of claim 1 , wherein the Clostridium disporicum comprises the 16S rDNA sequence set forth in SEQ ID NO: 518.
Assignees
Inventors
Classifications
Mouth and digestive tract, i.e. intraoral and peroral administration · CPC title
Antibiotics · CPC title
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
Encapsulation of particles, e.g. foodstuff additives · CPC title
Food compositions, function of food ingredients or processes for food or foodstuffs · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11464812B2 cover?
- Provided are therapeutic compositions containing Ecobiotic™ populations for prevention, treatment and reduction of symptoms associated with a dysbiosis of a mammalian subject such as a human.
- Who is the assignee on this patent?
- Seres Therapeutics Inc
- What technology area does this patent fall under?
- Primary CPC classification A61K35/74. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Oct 11 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).